Different Immunosuppressive Treatment in iMN
Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort
Peking Union Medical College Hospital
200 participants
Apr 14, 2021
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
1-2mg/kg/d p.o. with a target accumulated dose of 12g.
1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\>5/ul.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04745728